Diagnostics and therapeutics for arterial wall disruptive disorders
First Claim
1. A method for diagnosing, or determining a predisposition to developing, an arterial wall disruptive disorder in a subject, comprising detecting one or more genotypic or phenotypic markers for macular degeneration in the eye, wherein said marker is indicative of arterial wall disruptive disorder or of a predisposition to developing arterial wall disruptive disorder.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides diagnostics, therapeutics and drug screening assays for arterial wall disruptive disorders, based on the discovery of a high level of correlation between the incidence of arterial wall disruptive disorders and the incidence of Age Related Macular Degeneration (AMD). In one embodiment, the arterial wall disruptive disorder is an aortic aneurysm.
-
Citations
67 Claims
- 1. A method for diagnosing, or determining a predisposition to developing, an arterial wall disruptive disorder in a subject, comprising detecting one or more genotypic or phenotypic markers for macular degeneration in the eye, wherein said marker is indicative of arterial wall disruptive disorder or of a predisposition to developing arterial wall disruptive disorder.
-
22. A method for diagnosing, or determining a predisposition to, arterial wall disruptive disorder in a subject, comprising:
-
(a) isolating a nucleic acid from a subject, and (b) genotyping said nucleic acid;
wherein at least one allele from a macular degeneration-associated haplotype is predictive of an increased risk of arterial wall disruptive disorder. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
-
-
23. A method for diagnosing, or determining a predisposition to, arterial wall disruptive disorder in a subject, said subject having family members diagnosed with macular degeneration, comprising:
-
a) isolating a nucleic acid from a subject;
amplifying the nucleic acid with primers which amplify a region of a chromosome corresponding to a polymorphic marker for macular degeneration; and
c) analyzing the amplification product wherein the presence of a polymorphism indicative of an allele type linked to macular degeneration is indicative of an allele type linked to arterial wall disruptive disorder or a predisposition for developing arterial wall disruptive disorder.
-
-
24. A method for diagnosing, or determining a predisposition to, arterial wall disruptive disorder in a subject, said subject having family members diagnosed with macular degeneration, comprising:
-
(i) isolating a genomic nucleic acid from a subject;
(ii) amplifying short tandem repeat sequences in said genomic DNA to obtain a genotype;
(iii) comparing said genotype to the genotype of known DNA sequences to detect nucleotide sequence polymorphisms; and
(iv) determining the presence or absence of a polymorphism in the genomic DNA of said subject;
wherein the presence of a polymorphism indicative of an allele type linked to macular degeneration is indicative of an allele type linked to arterial wall disruptive disorder or a predisposition for developing arterial wall disruptive disorder.
-
-
35. A kit for diagnosing arterial wall disruptive disorder, comprising:
-
a) primers for amplifying a region of a chromosome having a polymorphism indicative of macular degeneration;
b) reagents for performing DNA amplification; and
c) reagents for analyzing the amplified nucleic acid.
-
- 36. A method for diagnosing, or detecting a predisposition to developing, an arterial wall disruptive disorder in a subject, comprising performing an immunoassay on a sample obtained from said subject using an antibody specific for a gene product indicative of macular degeneration, wherein detection of the presence of bound antibody indicates that the subject has macular degeneration or a predisposition to developing macular degeneration and therefore has an arterial wall disruptive disorder or a predisposition for developing an arterial wall disruptive disorder.
- 38. A method for treating or preventing the development of arterial wall disruptive disorder in a subject, comprising administering to a subject a pharmaceutically effective amount of a macular degeneration therapeutic.
-
44. A pharmaceutical composition useful for treating or preventing arterial wall disruptive disorder, comprising an effective amount of a macular degeneration therapeutic and a therapeutically acceptable carrier.
-
50. A method for identifying an agent for, or determining the efficacy of, an agent for treating or preventing arterial wall disruptive disorder in a subject, comprising:
-
(1) administering to a subject an agent at a non-toxic dosage; and
(2) determining whether drusen formation or neovascularization is inhibited or has resolved. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58, 59)
-
-
51. A method for identifying an agent for treating or preventing arterial wall disruptive disorder in a subject, comprising:
-
(a) contacting a non-human model for macular degeneration with an agent; and
(b) monitoring one or more markers of macular degeneration, wherein the absence or disappearance of one or more of said markers is indicative of the inhibition of arterial wall disruptive disorder.
-
- 60. An animal model for arterial wall disruptive disorder comprising an animal which has or is predisposed for developing macular degeneration, wherein the presence of, severity of, or predisposition for macular degeneration in said animal is indicative of the presence of, severity of, or predisposition for arterial wall disruptive disorder.
-
63. An animal model for arterial wall disruptive disorder comprising a transgenic animal which carries a genetically modified homolog of a human AMD-associated gene.
- 65. An animal model for arterial wall disruptive disorder comprising a transgenic animal which carries a genetically modified drusen-associated marker gene.
-
67. A kit for diagnosing arterial wall disruptive disorder comprising at least two antibodies selected from the group consisting of:
- an anti-elastin antibody, and anti-collagen antibody, an anti-chemokine antibody, and anti-vitronectin antibody.
Specification